The study funded by Meda Pharma S.p.A. assessed a proprietary nutraceutical formulation (NUT2) combining artichoke, bergamot, berberis, astaxanthin, folic acid, and chromium on cholesterol and heart health indicators. Researchers found that NUT2 showed promise as an adjunct to lifestyle changes for individuals with low-to-moderate cardiovascular risk whose lipid levels remain suboptimal.
Key Findings:
- Study Design: A randomized, double-blind, placebo-controlled trial with 90 adults.
- Intervention: Participants received either NUT2 or a placebo for 12 weeks alongside standardized dietary advice.
- Results:
- Significant reductions in total cholesterol and LDL cholesterol in the NUT2 group at both 6 and 12 weeks.
- Triglyceride levels were also lower with NUT2.
- Improvements in homocysteine, fasting insulin, and waist circumference.
- Decrease in metabolic syndrome prevalence with NUT2 versus an increase in the placebo group.
Tolerability:
The NUT2 supplement was well-tolerated, with no serious adverse effects reported.
Limitations:
The study acknowledged its short duration and small sample size, suggesting the need for larger, longer studies to validate the findings.
For further details, refer to the full study in Nutrients here.
